On Monday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) was -9.12%% drop from the session before settling in for the closing price of $10.42. A 52-week range for PHAT has been $2.21 – $19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 12.50%. When this article was written, the company’s average yearly earnings per share was at 42.39%. With a float of $37.85 million, this company’s outstanding shares have now reached $69.64 million.
Let’s determine the extent of company efficiency that accounts for 427 employees. In terms of profitability, gross margin is 86.23%, operating margin of -349.84%, and the pretax margin is -307.2%.
Phathom Pharmaceuticals Inc (PHAT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Phathom Pharmaceuticals Inc stocks. The insider ownership of Phathom Pharmaceuticals Inc is 45.79%, while institutional ownership is 47.84%. The most recent insider transaction that took place on May 21 ’25, was worth 14,609. In this transaction Director of this company bought 3,780 shares at a rate of $3.86, taking the stock ownership to the 59,403 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 6,300 for $3.32, making the entire transaction worth $20,919. This insider now owns 55,623 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.39% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
You can see what Phathom Pharmaceuticals Inc (PHAT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.24, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Looking closely at Phathom Pharmaceuticals Inc (NASDAQ: PHAT), its last 5-days average volume was 2.25 million, which is a jump from its year-to-date volume of 2.02 million. As of the previous 9 days, the stock’s Stochastic %D was 64.76%.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 71.81%, which indicates a significant increase from 63.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 270.14% in the past 14 days, which was higher than the 162.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.22, while its 200-day Moving Average is $8.98. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $10.42. Second resistance stands at $11.37. The third major resistance level sits at $12.15. If the price goes on to break the first support level at $8.69, it is likely to go to the next support level at $7.91. Now, if the price goes above the second support level, the third support stands at $6.96.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are 69,814K outstanding shares of the company, which has a market capitalization of 661.14 million. As of now, sales total 55,250 K while income totals -334,330 K. Its latest quarter income was 28,520 K while its last quarter net income were -94,320 K.
